IMEXF (Imagin Medical) Net Interest Income: $-0.38 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Imagin Medical Net Interest Income?

Imagin Medical IMEXF -99.00% Net Interest Income is $-0.38 Mil as of Jun. 2023.

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Imagin Medical's net interest income for the three months ended in Jun. 2023 was $-0.00 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.38 Mil.

Imagin Medical Net Interest Income Related Terms

Imagin Medical Net Interest Income Historical Data

* Premium members only.

The historical data trend for Imagin Medical's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagin Medical Net Interest Income Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.05 0.01 -0.01 -0.01

Imagin Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.37 -0.00

Imagin Medical Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Interest Income →
What does a Net Interest Income of $-0.38 Mil mean?
Imagin Medical (IMEXF) has a Net Interest Income of $-0.38 Mil as of Jun. 2023.
Is Imagin Medical's Net Interest Income too high?
Imagin Medical's current Net Interest Income is $-0.38 Mil.
How does Imagin Medical's Net Interest Income compare to ABT and SYK?
Imagin Medical's Net Interest Income of $-0.38 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Interest Income for a Medical Devices & Instruments company?
A good Net Interest Income depends on the Medical Devices & Instruments industry context. However, Net Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Interest Income mean?
A high Net Interest Income can signal that a stock is expensive relative to its fundamentals. Imagin Medical's current Net Interest Income is $-0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagin Medical stock overvalued right now?
Imagin Medical (IMEXF) has a current Net Interest Income of $-0.38 Mil. The current Net Interest Income is $-0.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Interest Income calculated?
Net Interest Income is calculated from a company's financial statements. For Imagin Medical (IMEXF), the current Net Interest Income is $-0.38 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.